Just five months after Novartis put down $310 million for IFM Therapeutics’ inflammation-focused unit, the Big Pharma has come back for more. This time, it is teaming up with IFM Due, the subsidiary ...
Novartis will team up with a subsidiary of IFM Therapeutics to develop immunotherapies designed to fight inflammatory and autoimmune diseases by inhibiting the cGAS/STING pathway. Mutations activating ...
Novartis has agreed to acquire a subsidiary of IFM Therapeutics for up to $1.575 billion, IFM said today, in a deal that will expand the pharma giant’s pipeline with one clinical and two pre-clinical ...
Novartis has acquired IFM Due, a subsidiary of IFM Therapeutics, for $90 million up front and milestone payments that could be worth $745 million. The deal grants Novartis rights to IFM Due’s full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results